The Mission Report

Biotech Showcase™ 2016

January 11 - 13, 2016

San Francisco


Biotech Showcase™ is an investor and networking conference that provides private and public biotechnology and life sciences companies with an opportunity to present, build their profile, conduct one-to-one meetings, and network with investors and pharmaceutical executives – all during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, BTS 2016 is expected to attract more than 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. BTS 2016 takes place January 11-13, 2016, in San Francisco. For more information about EBD Group's BTS conference, visit


Amedica Corp. (AMDA)

Amedica Corp. (NASDAQ: AMDA) develops Silicon Nitride orthopedic and spinal implants. It is the only company that has FDA approval to produce and distribute medical grade Silicon Nitride. Amedica's line of Silicone Nitride Interbody Fusion implants are designed to participate in the fusion process, optimizing patient outcomes. Along with spinal fusion implants, Amediac is developing a corrosion-resistant implant components for dental, hip and knee arthroplasty applications. For more information, visit the company's website at

Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, the company is addressing significant and growing markets where current treatment options are limited or inadequate. The company's product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which will have multiple indications. The company aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders. For more information, visit the company's website at

Bionomics Ltd. (BNOEF)

Bionomics Ltd. (OTC: BNOEF) is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system disorders such as depression, anxiety and Alzheimer's. Bionomics has created proprietary technology platforms for each step in the drug discovery and development process. One of the most notable platforms is Multicore, which involves a suite of integrated synthetic methods that gives access to complex drug-like molecules. For more information, visit the company's website at

Bio-Path Holdings, Inc. (BPTH)

Bio-Path Holdings, Inc. (NASDAQ: BPTH) is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systematically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company's initial focus is on cancer, and its lead candidate, BP1001, is in phase II study for blood cancers. Bio- Path's second drug candidate is ready for the clinic where it will be evaluated in lymphoma and solid tumors. For more information, please visit the company's website at

Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with pharmaceutical discovery and clinical development stage capabilities, developing treatments for cancer, inflammatory disease, and sexual dysfunction. The company's CF101 drug candidate is currently under advanced clinical development, preparing to enter phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug CF102 is in phase II trials for patients with advanced liver cancer. For more information, visit the company's website at

Celator Pharmaceuticals, Inc. (CPXX)

Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. For more information, visit the company's website at

Celsion Corporation (CLSN)

Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company, is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The company's lead program is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in phase III development for the treatment of primary liver cancer and phase II development for the treatment of recurrent chest wall breast cancer. For more information, visit the company's website at

Cesca Therapeutics, Inc. (KOOL)

Cesca Therapeutics, Inc. (NASDAQ: KOOL) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company is focused on developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Among others, Cesca's portfolio includes its SurgWerks™ Platform, a proprietary stem cell therapy point-of-care kit systems for treating vascular and orthopedic indications; and CellWerksTM Platform, a proprietary stem cell laboratory kit for processing target cells used in the treatments of oncological and hematological disorders. For more information, visit the company's website at

CorMedix, Inc. (CRMD)

CorMedix, Inc. (NYSE: CRMD) is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The company's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter-related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. For more information, visit the company's website at

DanDrit Biotech USA, Inc. (DDRT)

DanDrit Biotech USA, Inc. (OTC: DDRT) was founded in 2001 and is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. DanDrit was founded based on the research of Professor Jesper Zeuthen at the Danish Cancer Society (Kraeftens Bekaempelse). Dendritic cells are critical components of the immune system. The ability of dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit. The company's expertise in producing dendritic cells from a patient's blook is combined with conventional production methods to make new and advanced vaccines for cancer patients. For more information, visit the company's website at

Enumeral Biomedical Holdings, Inc. (ENUM)

Enumeral Biomedical Holdings, Inc. (OTC: ENUM) is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral's researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information, visit the company's website at

Intec Pharma Ltd. (NTEC)

Intec Pharma Ltd. (NASDAQ: NTEC) is developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa (AP-CDLD) for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon (AP-ZP) for treatment of insomnia; and a third Accordion Pill for the treatment of gastoduodenal and small bowel NSAID-induced ulcers. For more information, visit the company's website at

NanoViricides, Inc. (NNVC)

NanoViricides, Inc. (NYSE: NNVC) is a nano-biopharmaceutical company focused on discovering, developing, and marketing therapeutics for the treatment of viral infections. The company is developing anti-flu drug candidates at pre-clinical and advanced pre-clinical stage. These candidates include two FluCide drugs made up of NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Pathogenic Influenzas. For more information, visit the company's website at

Guided Therapeutics, Inc. (GTHP)

Guided Therapeutics, Inc. (OTC: GTHP) has developed a biophotonic technology for the early detection of disease that leads to cancer. The technology uses light to detect disease at the cellular level and provide immediate results at the time of the examination, decreasing waiting time and preventing false-positive results. The company's LuVia Advanced Cervical Scan is being utilized in Canada, Latin America, Europe, Asia and Africa and is under review in the U.S. LuViva is designed to determine the true likelihood of a treatable cervical disease in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result. For more information, visit the company's website

Heat Biologics (HTBX)

Heat Biologics (NASDAQ: HTBX) is developing novel therapies that activate a patient's immune system against cancer. The company's T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. In combination with other therapies, these platforms are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells; T cell co-stimulation to further enhance patients' immune response; and reversal of tumor-induced immune suppression. Heat is conducting a phase 2 trial with its HS-410 in patients with non-muscle invasive bladder cancer (NMIBC) and a phase 1b trial with its HS-110 in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, visit the company's website at

Intellipharmaceutics International, Inc. (IPCI)

Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time. This type of delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug. Hypermatrix technology is the company's propriety product and allows for the intelligent and efficient design of drugs through the precise control of several key variables including varying drug attributes and patient requirements. For more information, visit the company's website at

OncBioMune Pharmaceuticals, Inc. (OBMP)

OncBioMune Pharmaceuticals, Inc. (OTC: OBMP) is headquartered in Baton Rouge, Louisiana, and is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. The company's lead product, ProscaVax is scheduled to commence a phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. For more information, visit the company's website at

Pressure BioSciences, Inc. (PBIO)

Pressure BioSciences, Inc. (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The company's products are based on the unique properties of both constant and alternating (pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform used to safely and reproducibly control bio-molecular interactions. PBIO's primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery and design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications. For more information, visit the company's website at


For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2016 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975